Apparent diffusion coefficient histogram analysis stratifies progression-free and overall survival in patients with recurrent GBM treated with bevacizumab: a multi-center study

Pseudoprogression Following Chemoradiotherapy for Glioblastoma Multiforme

(2014) Paul Sanghera et al.   CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES

Treatment of Glioblastoma Multiforme with Radiotherapy and Concomitant and Adjuvant Temozolomide: Translation of Randomised Controlled Trial Evidence into Routine Clinical Practice

(2011) C. Herbert et al.   CLINICAL ONCOLOGY

Advances in MRI Assessment of Gliomas and Response to Anti-VEGF Therapy

(2011) Whitney B. Pope et al.   Current Neurology and Neuroscience Reports

Quantitative volumetric analysis of conventional MRI response in recurrent glioblastoma treated with bevacizumab

(2011) B. M. Ellingson et al.   NEURO-ONCOLOGY

Should biomarkers be used to design personalized medicine for the treatment of glioblastoma?

(2010) Michael Weller et al.   Future Oncology

Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group

(2010) Patrick Y. Wen et al.   JOURNAL OF CLINICAL ONCOLOGY

Quantitative MR in multi-center clinical trials

(2010) Edward Ashton   JOURNAL OF MAGNETIC RESONANCE IMAGING

Validation of functional diffusion maps (fDMs) as a biomarker for human glioma cellularity

(2010) Benjamin M. Ellingson et al.   JOURNAL OF MAGNETIC RESONANCE IMAGING

Standardization of relative cerebral blood volume (rCBV) image maps for ease of both inter- and intrapatient comparisons

(2010) Devyani Bedekar et al.   MAGNETIC RESONANCE IN MEDICINE

Response as a predictor of survival in patients with recurrent glioblastoma treated with bevacizumab

(2010) M. Prados et al.   NEURO-ONCOLOGY

ADC histograms predict response to anti-angiogenic therapy in patients with recurrent high-grade glioma

(2010) Martha Nowosielski et al.   NEURORADIOLOGY

A “Vascular Normalization Index” as Potential Mechanistic Biomarker to Predict Survival after a Single Dose of Cediranib in Recurrent Glioblastoma Patients

(2009) A. Gregory Sorensen et al.   CANCER RESEARCH

Pseudoprogression and pseudoresponse in the treatment of gliomas

(2009) Dieta Brandsma et al.   CURRENT OPINION IN NEUROLOGY

Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma

(2009) Henry S. Friedman et al.   JOURNAL OF CLINICAL ONCOLOGY

Imaging response criteria for recurrent gliomas treated with bevacizumab: Role of diffusion weighted imaging as an imaging biomarker

(2009) Rajan Jain et al.   JOURNAL OF NEURO-ONCOLOGY

Recurrent Glioblastoma Multiforme: ADC Histogram Analysis Predicts Response to Bevacizumab Treatment

(2009) Whitney B. Pope et al.   RADIOLOGY

Progression-free survival: An important end point in evaluating therapy for recurrent high-grade gliomas

(2008) Kathleen R. Lamborn et al.   NEURO-ONCOLOGY

Bevacizumab for recurrent malignant gliomas: Efficacy, toxicity, and patterns of recurrence

(2008) A. D. Norden et al.   NEUROLOGY